Abstract
This paper will summarize the clinical features of transfusion-related acute lung injury (TRALI) before the experimental and clinical literature on the pathogenesis of TRALI is reviewed. Several mechanisms by which leukocyte antibodies induce TRALI have been unraveled. Significant advances have also been made in the field of recipient-related factors that contribute to the development of TRALI. In contrast, the pathomechanism behind non-immune TRALI (associated with the transfusion of blood components which do not contain antibodies) is less well understood, especially since the relevance of mechanisms proposed earlier is questioned by recent findings. The diversity of newly described factors contributing to TRALI supports the previously proposed threshold model of TRALI, and an extension of that model including newly defined multipliers and attenuators of TRALI is emerging.
Keywords: Transfusion, acute lung injury, neutrophils, TRALI, threshold model, leukocyte antibodies, non-immune TRALI, Serious Hazards of Transfusion (SHOT), hypoxemia, inflammatory reaction
Current Pharmaceutical Design
Title:Transfusion-related Acute Lung Injury: An Overview
Volume: 18 Issue: 22
Author(s): Behnaz Bayat and Ulrich J. Sachs
Affiliation:
Keywords: Transfusion, acute lung injury, neutrophils, TRALI, threshold model, leukocyte antibodies, non-immune TRALI, Serious Hazards of Transfusion (SHOT), hypoxemia, inflammatory reaction
Abstract: This paper will summarize the clinical features of transfusion-related acute lung injury (TRALI) before the experimental and clinical literature on the pathogenesis of TRALI is reviewed. Several mechanisms by which leukocyte antibodies induce TRALI have been unraveled. Significant advances have also been made in the field of recipient-related factors that contribute to the development of TRALI. In contrast, the pathomechanism behind non-immune TRALI (associated with the transfusion of blood components which do not contain antibodies) is less well understood, especially since the relevance of mechanisms proposed earlier is questioned by recent findings. The diversity of newly described factors contributing to TRALI supports the previously proposed threshold model of TRALI, and an extension of that model including newly defined multipliers and attenuators of TRALI is emerging.
Export Options
About this article
Cite this article as:
Bayat Behnaz and J. Sachs Ulrich, Transfusion-related Acute Lung Injury: An Overview, Current Pharmaceutical Design 2012; 18 (22) . https://dx.doi.org/10.2174/1381612811209023236
DOI https://dx.doi.org/10.2174/1381612811209023236 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Gender Differences in the Clinical Presentation of Heart Disease
Current Pharmaceutical Design Pharmacological Intervention in Type 2 Diabetes Mellitus – A Pathophysiologically Reasoned Approach?
Current Diabetes Reviews Epidemiology of Diabetes Mellitus in the United Arab Emirates
Current Diabetes Reviews Potential Therapeutic Effects of Physical Exercise for Bipolar Disorder
CNS & Neurological Disorders - Drug Targets New and Emerging Antiresorptive Treatments in Osteoporosis
Current Drug Safety Role of Iron Deficiency and Overload in the Pathogenesis of Diabetes and Diabetic Complications
Current Medicinal Chemistry Systemic Inflammation, Infection, ApoE Alleles, and Alzheimer Disease: A Position Paper
Current Alzheimer Research Clinical Science of Calcium Channel Blocker to Inhibit Hypertensive Vascular Injury
Current Hypertension Reviews Microbiome Regulation of Autoimmune, Gut and Liver Associated Diseases
Inflammation & Allergy - Drug Targets (Discontinued) Targeting MCP-1 to Reduce Vascular Complications of Obesity
Recent Patents on Cardiovascular Drug Discovery Dendritic Cells: A Double-Edge Sword in Atherosclerotic Inflammation
Current Pharmaceutical Design Levosimendan Preoperative
Current Pharmaceutical Design Caring for Children with Medical Complexity: Definitions, Challenges and Solutions
Current Pediatric Reviews Drugs Polypharmacology by In Silico Methods: New Opportunities in Drug Discovery
Current Pharmaceutical Design The Role of Nutrition During the COVID-19 Pandemic: What We Know
Endocrine, Metabolic & Immune Disorders - Drug Targets Alterations in the Vascular Reactivity of Aorta in the Early and Late Phase of Adjuvant-Induced Arthritis in Rat
Vascular Disease Prevention (Discontinued) Soy Isoflavones and Cardiovascular Disease Epidemiological, Clinical and -Omics Perspectives
Current Pharmaceutical Biotechnology Lipoprotein-associated Phospholipase A2 and Coronary Heart Disease
Current Pharmaceutical Design Editorial [“Current Aging Science”: An Important Platform for Reporting Advances in Aging-related Research]
Current Aging Science The Relation Between the Chemical Structure of Flavonoids and Their Estrogen-Like Activities
Current Medicinal Chemistry